Research
Hormonal
Novel GLP-1-based therapeutics are rapidly advancing and may reshape the future landscape of obesity and type 2 diabetes treatment.
Practitioners should consider the potential of these novel agents in treating obesity and type 2 diabetes.
StrongSupportsmedium confidence
This review explores the mechanisms, clinical development, and therapeutic potential of these novel agents.
Why this rating
The abstract discusses a review of multiple novel agents and their potential.
Source
Novel GLP-1-based Medications for Type 2 Diabetes and Obesity
Jang Won Son et al. · Endocrine Reviews · 2025
DOI 10.1210/endrev/bnaf036
reviewCited 17×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →